Back to List View Graph View

Cabotegravir

Cabotegravir (CAB) is an integrase strand transfer inhibitor (INSTI) developed for the treatment and prevention of HIV-1 infection.

Where the papers sit

9 papers from the last 6 months study cabotegravir directly · updated from PubMed 10 Nov 2026

Those 9 are all about one subject.

  • Long-Acting HIV Treatment

    Long-acting cabotegravir, alone or with rilpivirine, is being evaluated as an alternative to daily oral HIV therapy, especially for people facing adherence challenges. Research centers on willingness to use injections, injection-schedule adherence, virological control and real-world effectiveness. Pharmacokinetic modelling addresses the prolonged tail phase, including pregnancy and postpartum, while formulation and population models support dosing decisions. Safety surveillance remains broadly reassuring, but injection timing, adverse events and prior HBV infection remain important clinical considerations.

    9 papers

NEW DIRECTION

Cabotegravir is examined as a nanoscale crystal material rather than as an antiretroviral intervention

The long-acting injectable cabotegravir formulation studied by the multidimensional electron-diffraction paper is treated as a crystallographic and materials-engineering subject: the work resolves cabotegravir’s structure within the formulation and relates particle shape to crystal structure, growth, and morphology models. This departs from the other papers’ therapeutic, pharmacokinetic, adherence, safety, and implementation roles for cabotegravir by making the drug itself an object of nanoscale structural analysis, with implications for understanding and engineering its sustained-release formulation. 42969722Nov

cabotegravir chemical structure

Papers

The 9 papers from the last 6 months that study cabotegravir directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Long-Acting HIV Treatment (9)
  1. Formulations at the Nanoscale: Multi-dimensional Electron Diffraction of Long-Acting Injectable, Cabotegravir. Molecular pharmaceutics · 2 Nov 2026 PMID 42969722
  2. Awareness of and Hypothetical Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Oral Pre-Exposure Prophylaxis Users Who Obtained the Medicine Online in China: Web-Based Cross-Sectional Study. Journal of medical Internet research · 28 Oct 2026 PMID 42950349
  3. Controlled adherence with long-acting injectable cabotegravir plus rilpivirine: determinants and clinical impact of injection-schedule adherence in the Spanish RELATIVITY cohort. AIDS (London, England) · 23 Oct 2026 PMID 42909514
  4. Long-Acting HIV Therapy in African Adults with Adherence Challenges. The New England journal of medicine · 14 Oct 2026 PMID 42874104
  5. Modelling the tail-phase pharmacokinetics of long-acting cabotegravir and rilpivirine from early pregnancy to postpartum at steady state. Journal of pharmacokinetics and pharmacodynamics · 23 Sept 2026 PMID 42778687
  6. Analytical description of adverse events with long-acting injectable cabotegravir and rilpivirine in people living with HIV: a large multicentre prospective observational cohort study (SCOLTA). HIV research & clinical practice · 21 Sept 2026 PMID 42765669
  7. Risk of Virological Failure After Switch to a Tenofovir-Sparing Dual Therapy in Virologically Suppressed People With HIV and Past HBV Infection. Journal of medical virology · 21 Jul 2026 PMID 42479941
  8. Real-World Safety and Effectiveness of Cabotegravir in People Living with HIV: Interim Report of a Post-marketing Surveillance in Japan. Advances in therapy · 16 Jul 2026 PMID 42461573
  9. External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV-Infected Patients. CPT: pharmacometrics & systems pharmacology · 22 May 2026 PMID 42170807

By study type

Clinical trials (2)
  1. Long-Acting HIV Therapy in African Adults with Adherence Challenges. The New England journal of medicine · 14 Oct 2026 PMID 42874104
  2. Risk of Virological Failure After Switch to a Tenofovir-Sparing Dual Therapy in Virologically Suppressed People With HIV and Past HBV Infection. Journal of medical virology · 21 Jul 2026 PMID 42479941
Observational studies and case reports (3)
  1. Awareness of and Hypothetical Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Oral Pre-Exposure Prophylaxis Users Who Obtained the Medicine Online in China: Web-Based Cross-Sectional Study. Journal of medical Internet research · 28 Oct 2026 PMID 42950349
  2. Analytical description of adverse events with long-acting injectable cabotegravir and rilpivirine in people living with HIV: a large multicentre prospective observational cohort study (SCOLTA). HIV research & clinical practice · 21 Sept 2026 PMID 42765669
  3. External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV-Infected Patients. CPT: pharmacometrics & systems pharmacology · 22 May 2026 PMID 42170807
Human data, design not indexed (2)
  1. Formulations at the Nanoscale: Multi-dimensional Electron Diffraction of Long-Acting Injectable, Cabotegravir. Molecular pharmaceutics · 2 Nov 2026 PMID 42969722
  2. Modelling the tail-phase pharmacokinetics of long-acting cabotegravir and rilpivirine from early pregnancy to postpartum at steady state. Journal of pharmacokinetics and pharmacodynamics · 23 Sept 2026 PMID 42778687
Unclassified: not yet indexed with MeSH (2)
  1. Controlled adherence with long-acting injectable cabotegravir plus rilpivirine: determinants and clinical impact of injection-schedule adherence in the Spanish RELATIVITY cohort. AIDS (London, England) · 23 Oct 2026 PMID 42909514
  2. Real-World Safety and Effectiveness of Cabotegravir in People Living with HIV: Interim Report of a Post-marketing Surveillance in Japan. Advances in therapy · 16 Jul 2026 PMID 42461573